ArticleDiabetology & metabolic syndrome2025
Cathepsin H increases the risk of diabetic retinopathy: evidence from Mendelian randomization and bioinformatic analysis.
Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Integrated multi-omics analysis: exploring the molecular regulatory mechanisms of HIV infection and identifying the key gene WFDC2.Clinical and experimental medicine · 2026Article
- Genetic Determinants of Microvascular Complications of Type 1 Diabetes Mellitus: New Data from a Replication Study.Biomedicines · 2026Article
- Multiomics Integration Prioritizes ZFP36L1 as a Candidate Susceptibility Gene Associated With Inflammatory and Angiogenic Pathways in Diabetic Retinopathy.Journal of diabetes research · 2026Article
- Cathepsin H drives hypoxia-associated inflammatory and angiogenic programs in diabetic retinopathy and represents a potential therapeutic target.International journal of biological sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundWhile lysosomal cathepsins are crucial in cellular homeostasis and may contribute to diabetic chronic complications, their precise causal relationships remain insufficiently characterized.
methodsThis study employed comprehensive multidimensional Mendelian randomization (MR) analyses to investigate potential causal associations between nine cathepsins (B, E, F, G, H, L2, O, S, and Z) and six diabetic chronic complications encompassing both microvascular (nephropathy, retinopathy, proliferative retinopathy, maculopathy, neuropathy) and macrovascular manifestations (peripheral angiopathy). The analytical framework incorporated generalized summary-data-based MR (GSMR), univariable MR, multivariable MR, summary-data-based MR (SMR), and cis-expression quantitative trait locus (cis-eQTL) MR approaches, utilizing data derived from publicly available genome-wide association studies (GWAS). To further characterize the biological relevance of identified cathepsins, we conducted multi-omics investigations including gene set enrichment analysis, CIBERSORT, single-cell RNA sequencing analysis to explore the expression level, immune infiltration and biological function of identified cathepsins. Furthermore, we performed mediation analyses to assess whether immune cells potentially mediate the causal pathways linking identified cathepsins to diabetic complications.
resultsBoth GSMR and univariable MR showed that Cathepsin H levels were causally associated with increased risks of overall diabetic retinopathy (DR), proliferative diabetic retinopathy (PDR), and diabetic maculopathy, validated by SMR and cis-eQTL MR analyses. Multivariable MR analysis further confirmed the independent causal role of Cathepsin H in PDR {inverse variance weighted (IVW): p = 0.003, OR = 1.054, 95% CI = 1.017–1.093} and diabetic maculopathy (IVW: p = 0.022, OR = 1.068, 95% CI = 1.009–1.130). Sensitivity analyses indicated no significant heterogeneity or pleiotropy for any of these cause associations. Bioinformatic analyses revealed upregulated Cathepsin H expression in DR patients, enriched in immune-inflammatory pathways. Single-cell RNA sequencing further highlighted its specific overexpression in NK cells of DR. No mediation by immunophenotypes was observed.
conclusionsOur integrative approach establishes Cathepsin H as a causal driver for DR and its subtypes, highlighting its potential as a therapeutic target and biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.